Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression Mateos MV, Hernández JM, Hernández MT, Gutiérrez NC, Palomera L, Fuertes M, García-Sánchez P, Lahuerta JJ, de la Rubia J, Terol MJ, Sureda A, Bargay J, Ribas P, Alegre A, de Arriba F, Oriol A, Carrera D, García-Laraña J, García-Sanz R, Bladé J, Prósper F, Mateo G, Esseltine DL, van de Velde H, San Miguel JF. Haematologica 93(4):560-5. FI: 6.416 (Q1) Low expression of ZHX2, but not RCBTB2 or RAN, is associated with poor outcome in multiple myeloma Armellini A, Sarasquete ME, García-Sanz R, Chillón MC, Balanzategui A, Alcoceba M, Fuertes M, López R, Hernández JM, Fernández-Calvo J, Sierra M, Megido M, Orfão A, Gutiérrez NC, González M, San Miguel JF. British Journal of Haematology 141(2):212-5. FI: 4.597 (Q1) The immunophenotype of different immature, myeloid and B-cell lineage-committed CD34() hematopoietic cells allows discrimination between normal/reactive and myelodysplastic syndrome precursors Matarraz S, López A, Barrena S, Fernandez C, Jensen E, Flores J, Bárcena P, Rasillo A, Sayagues JM, Sánchez ML, Hernández-Campo P, Hernández Rivas JM JM, Salvador C, Fernandez-Mosteirín N, Giralt M, Perdiguer L, Orfao A. Leukemia 22: 1175-83. FI: 8.296 (Q1) Prognostic Value of Immunophenotyping in Multiple Myeloma: A Study by the PETHEMA/GEM Cooperative Study Groups on Patients Uniformly Treated With High-Dose Therapy Mateo G, Montalbán MA, Vidriales MB, Lahuerta JJ, Mateos MV, Gutiérrez NC, Rosiñol L, Montejano L, Bladé J, Martínez R, de la Rubia J, Díaz-Mediavilla J, Sureda A, Ribera JM, Ojanguren JM, de Arriba F, Palomera L, Terol MJ, Orfao A, San Miguel JF. Journal of Clinical Oncology 1;26 (16):2737-44. FI: 17.793 (Q1) Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosis Cavazzini F, Hernández JA, Gozzetti A, Russo Rossi A, De Angeli C, Tiseo R, Bardi A, Tammiso E, Crupi R, Lenoci MP, Forconi F, Lauria F, Marasca R, Maffei R, Torelli G, Gonzalez M, Martín P, Hernández Rivas JM, Rigolin GM, Cuneo A. British Journal of Haematology 142: 529-37. FI: 4.597 (Q1) Transient t(11;17)(q14;q12) in patient with chronic myelogenous leukemia in complete molecular response Olazábal J, García JL, Gutiérrez NC, Sierra M, González M, Hernández JM. Cancer Genetics and Cytogenetics 186(2):125-6. FI: 1.537 (Q3) Primary mixed squamous carcinoma and osteosarcoma (carcinosarcomas) of the lung have a CGH mapping similar to primitive squamous carcinomas and osteosarcomas Pardo J, Aisa G, Alava E, Sola JJ, Panizo A, Rodríguez-Spiteri N, García JL, Torre W. Diagnostic Molecular Pathology 17(3):151-8. FI: 1.579 (Q3) Multiparameter flow cytometry remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation Paiva B, Vidriales MB, Cerveró J, Mateo G, Pérez JJ, Montalbán MA, Sureda A, Montejano L, Gutiérrez NC, García de Coca A, de Las Heras N, Mateos MV, López-Berges MC, García-Boyero R, Galende J, Hernández J, Palomera L, Carrera D, Martínez R, de la Rubia J, Martín A, Bladé J, Lahuerta JJ, Orfao A, San Miguel JF. GEM (Grupo Español de MM)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Groups. Blood 112(10):4017-23. FI: 10.555 (Q1) Sulforaphane and its analogues inhibit CYP1A1 and CYP1A2 activity induced by benzopyrene Skupinska K, Misiewicz-Krzemiska I, Lubelska K, Kasprzycka-Guttman T. Journal of Biochemical and Molecular 23(1):18-28. FI: 1.957 (Q3) Influence of protoporphyrin IX amino acid substituents on affinity to human breast adenocarcinoma MCF-7 cells Misiewicz-Krzemiska I, Skupinska K, Graczyk A, Kasprzycka-Guttman T. Biotechnic & Histochemistry 84(1):17-23. FI: 0.667 (Q4)
|
